SCHEMBL921069

SCHEMBL921069

Cc1ccc(Oc2cc[c]cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEAD4 Q15561 1/20 0.56
TDP1 Q9NUW8 3/20 0.54
ALDH1A1 P00352 2/20 0.54
POLB P06746 1/20 0.54
MAPT P10636 1/20 0.54
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
ACHE P22303 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.44
HTT P42858 2/20 0.44
MMP13 P45452 2/20 0.44
AR P10275 3/20 0.43
GAA P10253 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP3A4 P08684 1/20 0.39
TSHR P16473 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
LMNA P02545 1/20 0.38
HSD17B1 P14061 1/20 0.38
HSD17B2 P37059 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9871155 0.85 ACHE (0.46) TEAD4TDP1ALDH1A1POLBMAPT
SCHEMBL609237 0.84 LTA4H (0.44) TEAD4TDP1ALDH1A1POLBMAPT
SCHEMBL83863 0.84 TEAD4 (0.74) TEAD4TDP1ALDH1A1POLBMAPT
SCHEMBL83814 0.84 TEAD4 (0.74) TEAD4TDP1ALDH1A1POLBMAPT
SCHEMBL95343 0.84 TEAD4 (0.74) TEAD4TDP1ALDH1A1POLBMAPT
SCHEMBL919823 0.81 ALDH1A1 (0.59) TEAD4TDP1ALDH1A1POLBMAPT
SCHEMBL29377968 0.81 TEAD4 (0.70) TEAD4TDP1ALDH1A1POLBMAPT
SCHEMBL27689072 0.81 TEAD4 (0.70) TEAD4TDP1ALDH1A1POLBMAPT
Fluoride SCHEMBL27620675 0.81 TEAD4 (0.70) TEAD4TDP1ALDH1A1POLBMAPT
SCHEMBL919466 0.80 LTA4H (0.58) TDP1ALDH1A1POLBMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240002344-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION FIBROGEN, INC. 2024-01-04 US claimed
EP-4204400-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION Fibrogen, Inc. (US) 2023-07-05 EP claimed
CN-116348450-A Compounds, compositions and methods for histone lysine demethylase inhibition 菲布罗根有限公司 2023-06-27 CN claimed
CN-116143697-A Preparation method of tolfenpyrad 新沂市永诚化工有限公司 2023-05-23 CN claimed
WO-2022012550-A1 SUBSTITUTED 1H-IMIDAZO [1, 2-B] PYRAZOLE-3-CARBOXAMIDE AS BRUTON'S TYROSINE KINASE INHIBITORS HENAN NORMAL UNIVERSITY (CN) 2022-01-20 WO claimed
CN-108409837-B Glycopeptide compound with anti-drug resistance bacterial activity, preparation method and application thereof 上海来益生物药物研究开发中心有限责任公司 2021-09-24 CN claimed
EP-1465869-B1 MODULATORS OF LXR EXELIXIS PATENT CO LLC (US) 2013-05-15 EP claimed
CN-103080096-A Biaryl (thio) morpholine derivatives as S1P modulators ABBVIE BV 2013-05-01 CN claimed
US-7998986-B2 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US claimed
US-7737285-B2 Azole derivatives and fused bicyclic azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. (US) 2010-06-15 US claimed
US-20040082542-A1 Azole derivatives and fused bicyclic azole derivatives as therapeutic agents VTV THERAPEUTICS LLC 2004-04-29 US claimed
US-20030181420-A1 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS, INC. 2003-09-25 US claimed
WO-2003075921-A2 MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE TRANSTECH PHARMA, INC. (US) 2003-09-18 WO claimed
WO-2003059884-A1 MODULATORS OF LXR X-CEPTOR THERAPEUTICS, INC. (US) 2003-07-24 WO claimed
EP-1134214-A1 PICOLINAMIDE DERIVATIVES AND PEST CONTROLLERS CONTAINING THE SAME AS THE ACTIVE INGREDIENT MEIJI SEIKA KAISHA LTD. (JP) 2001-09-19 EP claimed
CN-1045966-A The monomer that contains the hexafluoro sec.-propyl, its preparation method and application HOECHST AG (DE) 1990-10-10 CN claimed
EP-0181292-B1 PROCESS FOR THE CONTINUOUS TRICHROMATIC DYEING OF SYNTHETIC POLYAMIDE MATERIALS CIBA-GEIGY AG (CH) 1990-07-25 EP claimed
US-4652269-A Process for the continuous trichromatic dyeing of synthetic polyamide materials: including a blue anthraquinone reactive dye CIBA-GEIGY CORPORATION (US) 1987-03-24 US claimed
EP-0181293-A2 Process for dyeing synthetic polyamide materials with anthrachinone reactive dyes CIBA-GEIGY AG (CH) 1986-05-14 EP claimed
EP-0181292-A2 Process for the continuous trichromatic dyeing of synthetic polyamide materials CIBA-GEIGY AG (CH) 1986-05-14 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181420-A1 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors NR1H2, NR1H3, NCOA1 TEAD4 522/4885TDP1 4087/4885ALDH1A1 2744/4885
US-20040082542-A1 Azole derivatives and fused bicyclic azole derivatives as therapeutic agents AGER, S100A4, S100B TEAD4 3510/4885TDP1 2323/4885ALDH1A1 3202/4885
US-20240002344-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION KDM5C, KDM5B, KDM5A TEAD4 923/4885TDP1 570/4885ALDH1A1 2449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.